CORT:NSD-Corcept Therapeutics Incorporated (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 52.17

Change

+1.27 (+2.50)%

Market Cap

USD 6.37B

Volume

0.26M

Analyst Target

USD 15.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+2.91 (+0.72%)

USD 120.60B
REGN Regeneron Pharmaceuticals Inc

-0.66 (-0.09%)

USD 84.94B
ARGX argenx NV ADR

+1.67 (+0.27%)

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

+0.99 (+0.41%)

USD 31.66B
BGNE BeiGene Ltd

+3.92 (+2.21%)

USD 20.24B
UTHR United Therapeutics Corporatio..

-2.78 (-0.76%)

USD 16.18B
MRNA Moderna Inc

+0.68 (+1.72%)

USD 16.10B
RPRX Royalty Pharma Plc

-0.02 (-0.08%)

USD 15.27B
SMMT Summit Therapeutics PLC

+0.33 (+1.77%)

USD 13.67B
INCY Incyte Corporation

+0.07 (+0.10%)

USD 13.52B

ETFs Containing CORT

SBIO ALPS Medical Breakthrough.. 4.07 % 0.50 %

-0.04 (0.79%)

USD 0.11B
FBT:LSE First Trust Global Funds .. 3.91 % 0.00 %

+8.20 (+0.79%)

USD 8.11M
FBTU:LSE First Trust Global Funds .. 3.91 % 0.00 %

+0.16 (+0.79%)

USD 8.11M
JPSE JPMorgan Diversified Retu.. 0.44 % 0.29 %

+0.24 (+0.79%)

USD 0.52B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

+0.74 (+0.79%)

N/A
FNX First Trust Mid Cap Core .. 0.00 % 0.62 %

+0.96 (+0.79%)

USD 1.33B
FNY First Trust Mid Cap Growt.. 0.00 % 0.70 %

+0.66 (+0.79%)

USD 0.40B
PSCH Invesco S&P SmallCap Heal.. 0.00 % 0.29 %

+0.19 (+0.79%)

USD 0.19B
SQLV Royce Quant Small-Cap Qua.. 0.00 % 0.60 %

+0.36 (+0.79%)

USD 0.03B
GSSC Goldman Sachs ActiveBeta.. 0.00 % 0.20 %

+0.58 (+0.79%)

USD 0.55B
ROSC Hartford Multifactor Smal.. 0.00 % 0.00 %

+0.46 (+0.79%)

USD 0.04B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 60.62% 85% B 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 60.62% 85% B 88% B+
Trailing 12 Months  
Capital Gain 60.92% 86% B+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 60.92% 86% B+ 88% B+
Trailing 5 Years  
Capital Gain 322.43% 96% N/A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 322.43% 96% N/A 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 26.25% 68% D+ 78% C+
Dividend Return 26.25% 68% D+ 77% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 39.21% 74% C 48% F
Risk Adjusted Return 66.93% 98% N/A 86% B+
Market Capitalization 6.37B 96% N/A 90% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.